今天,小编给大家分享一篇近期发表在Lung Cancer的文章,看看这些问题是否有了新的进展。 案例报道 今天要介绍的病人是一位44岁不抽烟的女性患者,因咳嗽、咳痰加重入院,17年8月通过CT、淋巴结和肺组织活检确诊为肺腺癌(IV期),免疫组化检查显示肺活检组织ALK阳性表达,此外患者进行了新一代测序(NGS)检查,发现癌组织中...
参考文献: Schneider, J.L., Lin, J.J. & Shaw, A.T. ALK-positive lung cancer: a moving target.Nat Cancer4, 330–343 (2023). https://doi.org/10.1038/s43018-023-00515-0 作者:墨竹 编辑人:💧Transparent 推文用于传递知识,如因...
Lung Cancer案例:特殊的ALK基因融合让非小细胞肺癌患者实现长期生存 我国晚期NSCLC患者ALK阳性的发生率为6.6%~7%,对于无法手术的晚期ALK患者,ALK抑制剂是一线首选,并逐渐形成了以一代克唑替尼、二代塞瑞替尼、阿来替尼、布加替尼、恩莎替...
Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung cancers; yet the durability of response is limited by drug resistance. Elucidation of on-target resistance mechanisms...
在不断研发新一代ALK抑制剂的同时,能否通过其他方法增加患者对靶向药物的敏感性,使患者可以长期受益于靶向治疗,能否有更先进的检测方法筛选出更适合靶向治疗的患者。今天,小编给大家分享一篇近期发表在LungCancer的文章,看看这些问题是否有了新的进展。 案例报道 ...
Dagogo-Jack I, Kiedrowski LA, Lennerz JK. Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy. Lung Cancer. 2023 Sep 23;186:107383. doi: 10.1016/j.lungcan.2023.107383. Epub ahead of print. PMID: 37813016....
Lung cancer link to ALK
[4]Leonetti Alessandro, Minari Roberta, Boni Luca, et al. Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial. Clin Lung Cancer, 2021, 22: 473-477. ...
4. Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study[J]. Ann Oncol, 2020, 31(8): 1056-1064. ...
⑥Descourt R, et al. Lung Cancer 2019;136:109–114.Solomon BJ, et al. Lancet Oncol 2018;19:1654–1667.Huber RM, et al. J Thorac Oncol 2020;15:404–415.D'Antonio C, et al. Ther Adv Med Oncol 2014;6:101–114. ⑦Liu C, et al. Front Oncol. 2019...